Stay updated on Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.

Latest updates to the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study page now displays a 403 Forbidden error page, replacing the previous study content with an access-denied screen. This shows a basic error layout with a 403 message and site footer, indicating restricted access rather than updated study details.SummaryDifference23%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page's Revision tag was updated from v3.6.5 to v3.6.6, reflecting a new version of the page metadata.SummaryDifference0.0%

- Check56 days agoChange DetectedPlatform revision updated from v3.6.4 to v3.6.5, indicating a minor backend/UI release. No visible changes to the study page content are evident.SummaryDifference0.0%

- Check63 days agoChange DetectedUPMC Hillman Cancer Center was added as a participating site for the study. University of Pittsburgh Cancer Institute (UPCI) was removed.SummaryDifference0.2%

- Check70 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4. This update reflects a new page template/version used for the study page, without altering its content.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page's revision tag was updated to v3.6.3, indicating a minor update to the page version without changing study information.SummaryDifference0.0%

Stay in the know with updates to Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.